Over the years, ChEMBL has accepted 336 datasets deposited by the community. In fact, these data now comprise around 50% of the bioactivity data points. This is in addition to ChEMBL’s core data, bioactivity data extracted from the medicinal chemistry literature, and drug and clinical candidate data curated from regulatory authorities and clinical trials. However, ChEMBL - like many other open access databases - is currently facing a reduction in funding. While we remain committed to maintaining the core of ChEMBL’s literature-extracted bioactivity data as well as drug data annotations, these constraints mean that in the future we may not be able to accept data depositions unless they are accompanied by appropriate funding. This applies particularly to those that require extensive curation or substantial manual intervention (*). Any depositions that have been agreed or are already in progress will be handled as planned. Beyond this, we will continue to prioritise depositions that a...
photo by B. Zdrazil, Wellcome Genome Campus in morning glory, Dec. 2025 The Chemical Biology Services Team is looking back at a year full of changes, new beginnings, and the farewell of a few long-standing team members. In February, we welcomed our new Team Leader Noel O'Boyle . He brought fresh perspectives and new energy to the team, but he also had to see several team members leave as they reached the end of their contracts. We are grateful for all the contributions that Eloy Felix, Fiona Hunter, David Mendez, Juan Mosquera, A. Lina Heinzke, Cote Falguera, Melanie Schneider, and Sybilla Corbett have made to our great resources: ChEMBL, SureChEMBL, ChEBI & UniChem. 2025 has been a very productive year! OPSIN found a new home under the EBI umbrella, ChEMBL 36 - the largest data release for ChEMBL ever - was released in autumn, ChEBI 2.0 was launched and its restructuring has been published in a recent NAR article . The team also made some great advances to push ...